134
Participants
Start Date
May 26, 2017
Primary Completion Date
September 27, 2019
Study Completion Date
October 25, 2019
GDC-0853
GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
Placebo
Matching Placebo will be administered orally, as per the dosing schedules described above.
Charite Mitte; Klinik fur Dermatologie, Berlin
Hautarztpraxis Mahlow, Mahlow
New Horizon Research Center, Miami
Renstar Medical Research, Ocala
Clinical Research Center of Alabama, LLC, Birmingham
Klinik für Haut- und Geschlechtskrankheiten, Universitätsklinikum Münster, Münster
Universitätsmedizin Johannes Gutenberg Universität, Mainz
Vital Prospects Clinical Research Institute PC - CRN, Tulsa
Center for Clinical Studies, Cypress
Allergy & Asthma Immunology Associates, Scottsdale
Licca Clinical Research Institute, Augsburg
Integrated Research of Inland, Upland
Integrated Research Group Inc, Riverside
Southern California Research Center, Mission Viejo
Kern Allergy Med Clinic, Inc., Bakersfield
Allergy & Asthma Consultants, Redwood City
Asthma, Nasal Disease, and Allergy Research Center of New England, East Providence
Timber Lane Allergy and Asthma Research, LLC, Burlington
University of British Columbia, Vancouver
Private Practice - Dr. Jason Ohayon, Hamilton
Lynde Institute for Dermatology, Markham
Cheema Research, Mississauga
Yang Medicine, Ottawa
Gordon Sussman Clinical Research, Toronto
Private Practice - Dr. Isabelle Delorme, Drummondville
Centre de Recherche Applique En Allergie de Quebec, Québec
Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Augenheilkunde, Dresden
Lead Sponsor
Genentech, Inc.
INDUSTRY